MODERATE TO SEVERE ASTHMA
Clinical trials for MODERATE TO SEVERE ASTHMA explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE ASTHMA trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE ASTHMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New asthma drug aims to cut severe attacks in Half-Year trial
Disease control Not yet recruitingThis study is testing an investigational injection called CM326 to see if it can reduce severe asthma flare-ups and improve lung function and quality of life in adults with moderate to severe asthma. About 230 participants will receive either CM326 or a placebo injection for 52 w…
Matched conditions: MODERATE TO SEVERE ASTHMA
Phase: PHASE3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 02:41 UTC
-
New pill targets root of asthma inflammation in global trial
Disease control Not yet recruitingThis study is testing an experimental pill called linvemastat as an add-on treatment for adults whose moderate-to-severe asthma isn't fully controlled by their standard inhalers. About 135 participants will take either the new drug or a placebo pill daily for 16 weeks while conti…
Matched conditions: MODERATE TO SEVERE ASTHMA
Phase: PHASE2 • Sponsor: Foresee Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New asthma shot aims to help Hard-to-Control breathing
Disease control Not yet recruitingThis study is testing an investigational injection called RC1416 for adults whose moderate to severe asthma is not well controlled with standard inhalers. About 195 participants will receive either the injection or a placebo to see if it improves lung function and reduces serious…
Matched conditions: MODERATE TO SEVERE ASTHMA
Phase: PHASE2 • Sponsor: Nanjing RegeneCore Biotech Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC